For HCPs Only
Recent Clinical Updates
Loading latest clinical updates

Clinical Intelligence & Drug Records for US-Licensed Practitioners

The integrated, institutional-grade registry trusted by US-licensed practitioners for evidence-based clinical data, drug information, and peer-reviewed drug updates.

Drug Update Briefing

Weekly drug approvals, safety updates, and specialty coverage for healthcare professionals.

Clinical Resources

Drug updates, reference data, and specialist-led coverage.

Recent Clinical Updates

Latest Drug & Specialty Updates

View All

Specialty Coverage

Therapeutic-area updates for clinical review.

All Specialties

Drug Information

FDA drug records and prescribing context.

Review drug records, NDC references, dosage tools, and interaction resources alongside clinical coverage.

FDA data

Drug Reference

Drug approvals, labels, and clinical context.

Access structured FDA label data, dosage references, NDC records, interactions, and prescribing context.

Clinical Coverage

Additional Drug Updates

Cardiology

FDA Approves Semaglutide for HFpEF: 20% Reduction in Heart Failure Events

0h ago|3 min read|By Dr. Arjun Sharma
Rheumatology

FDA Warns of Increased Cardiovascular and Cancer Risks with JAK Inhibitors in Rheumatoid Arthritis

0h ago|3 min read|By Dr. Deepak Nair
Neurology

FDA Approves Lecanemab for Alzheimer: 27% Cognitive Decline Reduction

0h ago|3 min read|By Dr. Aditi Kulkarni
Pulmonology

Severe Asthma Biologics Comparison: Mepolizumab, Benralizumab, Dupilumab, Tezepelumab, and Depemokimab Insights for 2026

0h ago|2 min read|By Dr. Nikhil Chatterjee
Dermatology

Atopic Dermatitis Biologics Comparison: Dupilumab, Tralokinumab, Lebrikizumab, and JAK Inhibitors

0h ago|3 min read|By Dr. Rohan Gupta
Cardiology

HFpEF Management 2026: SGLT2 Inhibitors and Spironolactone Show Mixed Results

0h ago|3 min read|By Dr. Kavya Sharma
Neurology

FDA Approves Lecanemab for Alzheimer: Biweekly IV vs Weekly Subcutaneous Administration

0h ago|3 min read|By Dr. Aditi Kulkarni
Cardiology

Baxdrostat Reduces Resistant Hypertension: Comparison with Spironolactone and Eplerenone

0h ago|3 min read|By Dr. Kavya Sharma
Endocrinology

GLP-1 Receptor Agonists 2026: Comprehensive Comparison of Orforglipron, Tirzepatide, and Semaglutide

0h ago|3 min read|By Dr. Amit Desai
Oncology

FDA Approves Vepdegestrant for ESR1-Mutated Breast Cancer: 5-Month PFS Improvement Over Fulvestrant

0h ago|3 min read|By Dr. Rahul Verma
Neurology

FDA Approves Tolbrutinib for Progressive MS: New BTK Inhibitor in Treatment Algorithm

0h ago|3 min read|By Dr. Aditi Kulkarni
Policy

CMS Proposes 2026 Reform: Gold Carding Exemptions to Ease Medicare Advantage Burden

0h ago|3 min read|By Editorial Team
Neurology

FDA Extends PDUFA for Lecanemab Autoinjector: Weekly Home Administration for Alzheimer’s

0h ago|3 min read|By Dr. Vikram Patel
Endocrinology

ADA Updates Diabetes Treatment Guidelines: GLP-1 and SGLT2 Prioritized for Cardiovascular and Kidney Outcomes

0h ago|3 min read|By Dr. Amit Desai
Dermatology

Deucravacitinib and Tapinarof: New Oral Options for Plaque Psoriasis Treatment

0h ago|3 min read|By Dr. Rohan Gupta
Neurology

FDA Approves Efgartigimod for Myasthenia Gravis: New Treatment Algorithm for Seropositive and Seronegative Patients

0h ago|3 min read|By Dr. Vikram Patel
Pharmacology

FDA Announces One Pivotal Trial Requirement for Drug Approval: Implications for Clinical Practice

0h ago|3 min read|By Editorial Team
Pulmonology

Cytisinicline vs Varenicline: Comparative Efficacy in Smoking Cessation

0h ago|3 min read|By Dr. Nikhil Chatterjee
Neurology

CGRP Inhibitors for Migraine Prevention: Comparing Erenumab, Fremanezumab, Atogepant, and Rimegepant

0h ago|3 min read|By Dr. Aditi Kulkarni
Neurology

FDA Approves Lecanemab Subcutaneous Autoinjector for Alzheimer: Weekly Home Administration vs Biweekly IV

May 12|3 min read|By Dr. Aditi Kulkarni
Neurology

FDA Approves Lecanemab for Alzheimer: Coverage Criteria and MACE Monitoring

May 12|3 min read|By Dr. Vikram Patel
Rheumatology

FDA Approves Deucravacitinib for Psoriatic Arthritis: TYK2 Inhibition Reduces Disease Activity

May 12|3 min read|By Dr. Deepak Nair
Endocrinology

FDA Approves Langlara: New Biosimilar Insulin for Cost-Effective Diabetes Management

May 12|3 min read|By Dr. Amit Desai